{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:44:47Z","timestamp":1790016287932,"version":"4.0.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/M008665\/1"],"award-info":[{"award-number":["MR\/M008665\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003185","name":"National Psoriasis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002102","name":"King's Health Partners","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR302258"],"award-info":[{"award-number":["NIHR302258"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010377","name":"National Institute for Health and Care Excellence","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010377","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jid.2025.01.031","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:14:10Z","timestamp":1739992450000},"page":"2251-2260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Personalizing Biologic Therapy in Psoriasis: Development, Validation, and User Testing of a Precision-Dosing Dashboard"],"prefix":"10.1016","volume":"145","author":[{"given":"Charlotte M.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Baudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra","family":"Arkir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bola","family":"Coker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejus","family":"Dasandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kingsley","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Arenas-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystal","family":"Rawstron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chioma","family":"Nwaogu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Woolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Standing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satveer K.","family":"Mahil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2025.01.031_bib1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamadermatol.2019.4897","article-title":"Comparison of tightly controlled dose reduction of biologics with usual care for patients with psoriasis: a randomized clinical trial","volume":"156","author":"Atalay","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2025.01.031_bib2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/bjd\/ljac024","article-title":"Biologic tapering for patients with psoriasis with low disease activity: data from the French PsoBioTeq Registry","volume":"188","author":"Aubert","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.01.031_bib3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1080\/10447310802205776","article-title":"An empirical evaluation of the system usability scale","volume":"24","author":"Bangor","year":"2008","journal-title":"Int J Hum Comput Interact"},{"key":"10.1016\/j.jid.2025.01.031_bib4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ad.2015.02.003","article-title":"Dose modification in biologic therapy for moderate to severe psoriasis: a descriptive analysis in a clinical practice setting","volume":"106","author":"Baniandr\u00e9s","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.jid.2025.01.031_bib5","first-page":"1584","article-title":"Down-titration of infliximab:the real-life use in psoriatic patients","volume":"15","author":"Bardazzi","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jid.2025.01.031_bib6","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/bjd.15722","article-title":"Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)","volume":"177","author":"Blauvelt","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.01.031_bib7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2025.01.031_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.01.031_bib9","series-title":"Usability evaluation in industry","first-page":"189","article-title":"SUS: a quick and dirty usability scale","author":"Brooke","year":"1996"},{"key":"10.1016\/j.jid.2025.01.031_bib11","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3109\/09546634.2015.1034070","article-title":"Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice","volume":"26","author":"Carrascosa","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jid.2025.01.031_bib12","author":"Chang"},{"key":"10.1016\/j.jid.2025.01.031_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/ijd.16915","article-title":"Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting","volume":"63","author":"Daud\u00e9n","year":"2024","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jid.2025.01.031_bib15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/jdv.14145","article-title":"Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study","volume":"31","author":"Esposito","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2025.01.031_bib16","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","article-title":"Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial","volume":"160","author":"Eyerich","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2025.01.031_bib17","article-title":"RxODE: facilities for simulating from ODE-based models","author":"Fidler","year":"2024","journal-title":"R package version 2.1.3"},{"key":"10.1016\/j.jid.2025.01.031_bib18","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/j.1468-3083.2011.04290.x","article-title":"Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre","volume":"26","author":"Fotiadou","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2025.01.031_bib19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3390\/jcm13020495","article-title":"Effectiveness, tolerability, and drug survival of risankizumab in a real-world setting: a three-year retrospective multicenter study-IL PSO (Italian LANDSCAPE PSORIASIS)","volume":"13","author":"Gargiulo","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jid.2025.01.031_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.12688\/wellcomeopenres.16718.1","article-title":"An automated approach to identify scientific publications reporting pharmacokinetic parameters","volume":"6","author":"Gonzalez Hernandez","year":"2021","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.jid.2025.01.031_bib21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2340\/00015555-2571","article-title":"Adalimumab dose tapering in psoriasis: predictive factors for maintenance of complete clearance","volume":"97","author":"Hansel","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2025.01.031_bib23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40261-023-01280-9","article-title":"Real-world performance of a new strategy for off-label use of guselkumab in moderate to severe psoriasis: super-responder patients as the epitome of efficacy and optimisation","volume":"43","author":"Herranz-Pinto","year":"2023","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jid.2025.01.031_bib24","doi-asserted-by":"crossref","DOI":"10.2196\/37290","article-title":"System Usability Scale benchmarking for digital health apps: meta-analysis","volume":"10","author":"Hyzy","year":"2022","journal-title":"JMIR MHealth UHealth"},{"key":"10.1016\/j.jid.2025.01.031_bib27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2025.01.031_bib28","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3389\/fphar.2020.00620","article-title":"Software tools for model-informed precision dosing: how well do they satisfy the needs?","volume":"11","author":"Kantasiripitak","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jid.2025.01.031_bib29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/cpt.1594","article-title":"Exposure-response relationships for efficacy and safety of risankizumab in phase II and III trials in psoriasis patients","volume":"107","author":"Khatri","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jid.2025.01.031_bib30","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/psp4.12689","article-title":"Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr","volume":"10","author":"Le Louedec","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jid.2025.01.031_bib31","author":"Mahil"},{"key":"10.1016\/j.jid.2025.01.031_bib32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/09546634.2012.660520","article-title":"Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature","volume":"24","author":"Mahil","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jid.2025.01.031_bib33","article-title":"Risankizumab shows high efficacy and maintenance in improvement of response until week 52","volume":"35","author":"Mastorino","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2025.01.031_bib34","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/jamadermatol.2014.5479","article-title":"Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: a step toward personalized treatment","volume":"151","author":"Menting","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2025.01.031_bib35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40265-020-01448-z","article-title":"Dose tapering of biologics in patients with psoriasis: a scoping review","volume":"81","author":"Michielsens","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jid.2025.01.031_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115421","article-title":"Model-informed precision dosing: state of the art and future perspectives","volume":"215","author":"Minichmayr","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jid.2025.01.031_bib37","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/jdv.13884","article-title":"Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis","volume":"31","author":"Mostafa","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2025.01.031_bib39","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1111\/jdv.16256","article-title":"Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate-to-severe psoriasis","volume":"34","author":"Ovejero-Benito","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2025.01.031_bib40","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jid.2025.01.031_bib41","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.3390\/pharmaceutics14122731","article-title":"Model-informed precision dosing (MIPD)","volume":"14","author":"P\u00e9rez-Blanco","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jid.2025.01.031_bib42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2340\/00015555-2209","article-title":"Down-titration of adalimumab and etanercept in psoriatic patients: a multicentre observational study","volume":"96","author":"Piaserico","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2025.01.031_bib44","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2025.01.031_bib45","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.18143","article-title":"Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.01.031_bib46","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2025.01.031_bib47","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3390\/pharmaceutics16101295","article-title":"Model-informed precision dosing for personalized ustekinumab treatment in plaque psoriasis","volume":"16","author":"Rodr\u00edguez-Fern\u00e1ndez","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jid.2025.01.031_bib48","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3109\/09546634.2015.1088127","article-title":"Efficiency of biological therapies in patients with moderate to severe psoriasis: impact of a pharmacotherapeutic protocol","volume":"27","author":"Romero-Jimenez","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jid.2025.01.031_bib49","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/bcp.14410","article-title":"Bayes-based dosing of infliximab in inflammatory bowel diseases: short-term efficacy","volume":"87","author":"Santacana Juncosa","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jid.2025.01.031_bib50","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1080\/09546634.2020.1832649","article-title":"Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey","volume":"33","author":"Schots","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jid.2025.01.031_bib51","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2025.01.031_bib52","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/jdv.20074","article-title":"Exposure-response relationship of guselkumab and the potential of serum proteomics in identifying predictive biomarker candidates in psoriasis","volume":"38","author":"Soenen","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2025.01.031_bib53","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/00365521.2020.1856405","article-title":"Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial","volume":"56","author":"Strik","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jid.2025.01.031_bib54","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40262-019-00759-z","article-title":"Population pharmacokinetics of risankizumab in healthy volunteers and subjects with moderate to severe plaque psoriasis: integrated analyses of phase I-III clinical trials","volume":"58","author":"Suleiman","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jid.2025.01.031_bib55","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/psp4.13056","article-title":"Tutorial on model selection and validation of model input into precision dosing software for model-informed precision dosing","volume":"12","author":"Taylor","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jid.2025.01.031_bib56","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2025.01.031_bib57","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/phar.2191","article-title":"Review and validation of Bayesian dose-optimizing software and equations for calculation of the vancomycin area under the curve in critically ill patients","volume":"38","author":"Turner","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jid.2025.01.031_bib58","year":"2024","journal-title":"NextDose"},{"key":"10.1016\/j.jid.2025.01.031_bib59","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cpt.2065","article-title":"A model averaging\/selection approach improves the predictive performance of model-informed precision dosing: vancomycin as a case study","volume":"109","author":"Uster","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jid.2025.01.031_bib60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/FTD.0000000000000420","article-title":"Prolongation of biologic dosing intervals in patients with stable psoriasis: a feasibility study","volume":"39","author":"van Bezooijen","year":"2017","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jid.2025.01.031_bib61","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00403-021-02273-4","article-title":"Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide","volume":"314","author":"van Muijen","year":"2022","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jid.2025.01.031_bib62","article-title":"Dose reduction of biologics in patients with plaque psoriasis: a review","volume":"15","author":"van Riel","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jid.2025.01.031_bib63","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.01.031_bib64","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/bjd.17036","article-title":"Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"180","author":"Yiu","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2025.01.031_bib65","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25001186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X25001186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:22:10Z","timestamp":1777641730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X25001186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0022202X25001186"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2025.01.031","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalizing Biologic Therapy in Psoriasis: Development, Validation, and User Testing of a Precision-Dosing Dashboard","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2025.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}